DOCSLIB.ORG

Third Release

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Third Release 2012 Established Aggregate Production Quotas • Section 306(a) of the Controlled Substances Act (CSA) requires the Attorney General to establish limits on the production of schedules I and II controlled substances. This responsibility has since been delegated to the Administrator of the Drug Enforcement Administration (DEA). • The regulations require that DEA revise the aggregate production quota (APQ) annually after review of pertinent information provided from various sources including DEA-registered manufacturers and the Food and Drug Administration (FDA). • The attached Federal Register seeks to establish the APQ for 2012. A table summarizing the APQ and the changes made to the proposed established value are attached for reference. • OD is recommending an increase in the APQ for alfentanil. This increase is based on increased exportation requirements. • OD is recommending an increase in the APQ for dihydrocodeine. This increase is based on increased manufacturing requirements. • OD is recommending an increase in the APQ for diphenoxylate. This increase is based on increased sales. • OD is recommending an increase in the APQ for bydromorphinol. This increase is based on the increased need for reference standards. • OD is recommending an increase in the APQ for lisdexamfetamine. This increase is based on increased exportation requirements. • OD is recommending an increase in the APQ for meperidine. The increase is due to increased sales. • OD is recommending an increase in the APQ for meperidine intermediate A. This increase is based on the increased need for reference standards. • OD is recommending an increase in the APQ for meperidine intermediate B. This increase is based on the increased need for reference standards. • OD is recommending an increase in the APQ for meperidine intermediate C. This increase is based on the increased need for reference standards. • OD is recommending an increase in the APQ for morphine-N-oxide. This increase is based on the increased need for reference standards. • OD is recommending an increase in the APQ for nabilone. The increase is to support product development efforts. DEA/OD/ODQ Vol. I Page 433 • OD is recommending an increase in the APQ for pentobarbital. The increase is due to increased sales and because'(f)(4) ]now properly assesses their quota at the initial manufacturing stage vs. the final finished product. The majority ofthis increase is accounting for their manufacturing losses. • OD is recommending an increase in the APQ for properidine. This increase is based on the increased need for reference standards. • OD is recommending an increase in the APQ for tapentadol. This increase is to support product development efforts. Currently Tapentadol ether is manufactured outside the US, the product development efforts will allow a shift to domestic manufacturing. DEA/OD/ODQ Vol. I Page 434 Aggregate Production Quotas (all values are In grams unless Indicated otherwise) Controlled Substance Final Revised initial Final Revised Proposed Initial Initial N.N-Oimethylamphetamine 2 2 "2 2 2 N-EihylaVphetamirieI : 2 2 2 2 N-Hydroxy-3.4-Methylenedioxyamphetamine i- 2 2 2 2 2012 Schedule!;.. 2010 2011 2011 2012"" Noracymethadol 2 2 2 2 2 NorJcyorphanoJ__ _. 52 _« 52 52 52 Normethadone • 2 2 2 2. 2 Normorphine . 16 18 18 18 13 Para-fluorofenlanyl 2 2 2 2 2 Phenomorphan 2 2 2 2 2 Phojcodine 2 2 2 2 2 - j Psilocybin 2 2 2 2 Psiiocyn . 2 2 2 2 2 Tetrahydrocannabinols 264.000 393,000 393,000 393,000 393,000 Thiofentanyl . 2 2 2 2 2 Tilidine "" *" " 10 10 10 10 '10 Trimeperidine 2 2 2 2 2 Controlled Substance Final Revised Initial Final Revised Proposed Initial Initial Schedule II: 2010 2011 2011 2012 2012 1-Phenyfcyclohexylamine 2 2 2 2 2 l-Piperdinocyclohexanecarbonitrile 0 1 2 2 4-Anilino-N-phenethyl-4-piperidine (ANPP) 1.100,000 2,500,000 1 .800,0001 1.800,000 1,800,000 Alfentanil 8,000 6,000 12,800; 11,600 15,000 Aiphaprodine _ 2 2 2 2 2 Amobarbjtal 3 40,007 40.007! 40,007 40,007 Amphetamine (for conversion) 7,500,000 7,500,000 8,500,000 8,500,000 8.500,000 Amphalamine (for sale) 18,600,000 18.600,000 26,300,000 25,300,000 _ 25,300.000 CarfenTanil 200 0 0 0 0 Cocaine : 247,000 247,000 __.216JOO 216,000 216,000 Codeine (for conversion) I 65,000,000 V5.b6b.000 65,000,000 65,000,000 65,000,000 Codeine (for salel . " 39,605.000" 39,605,000 39,605,000 39,60S,000 39,605,000 Oextropropoxyphene 92,000,000 92,000,000 7 7 7 Dihydrccodeine _ 800,000 800,000 _ 255,000 _255.000 400,000 Diphenoxylate ' ' 827,000 827,000 " 730,000 foo'obo ' 900,000 Ecgonjne 83,000 83,000 83,000 63,000 83,000 Ethylmorphine 2 2 . 2 2 2 Fenlanyl 1,423,000 1,428,000 1,426,000 1,426,000 1 ,423000 GlJtethimide . IJ2_ 2l"_" 2 2,~_ 2= Hydrocodone (for sale) 55.QOO.OOV 55,000,000! 59,000,000 "59,000,000 59,000,000 Hydromorphone 3.455,000: • 3,455.OOOl ~ 3,455.000 3,455,000 3,455,000 isomethadone 11 jT~ 2 4 A Levo-alphacetylmethadol (LAAM) 3 3 3 3 Levomethorphan 5 2 2 2 Levorphanol 10,000 10,000 3,600 3,600 3,600 Lisdexamfetamine 9,000.000 9,000,000 10,400,000 10,400,000 12,000,000 Meperidine ... 6,600,000 6,600,000 5,500,000 5,200,000 _5. 500, 000 M e p e ridine Intermediate-A 3 3 3 3 5 Meperidine Intermediale-B 7 7 7 7 9 Meperidine Intermediate-C 3 3 3 3 5 Melazocine 5 5 5 5 Methadone (for sale) 20,600.0001 20,000,000 20,000,000 20,000,000 20.000,000 Methadone Intermediate 26.000.0001 26,000,000 26,000,000 " 26.000,000 26,000,000 Methampheiamine 3,130,0001" ""3,130.000 3,130,000 3,130,000 3,130,000 750,000 750,000 " 750,000 750,000 _ levo-desoxvephedrine 7S0.000 meth amphelam ire (for convers ion! 2,331,000 2,331,000 2.331,000 2,331,000 2,331,000 _ methamphetamine (for sale) 49,0001 49,000 ' 49,000 49,000 49,000 Melhylphenidale 50,000,0001 50,000,000 56,000,000 56,000,000 56,000,000 Morphine (for conversion) 63.OOQ.OOOI ~ 83.000.000 70,000,000 83^000,000 83,000,000 Morphine (for sale) 39,000,000 39,000,000 39,000,000 39.000.000 39,000,000, Nabilono 9.002 10,502 10,5021 10,502 20,5021 Noroxymqrphonejfor conversion) 9.000.0001 9,000,000 7,200,0001 7,200,000 7,200,000 Koroxymorphone (for sale) 41,000 401,0001 401,000 401,000 401,000 Opium (powdered) 230,000. 230,000 _ 63,000 _ 63,000 63,000 Opium (tincture) " i?5QQ,dbo "1 .500.000 1,000,000 1,000,000 1,000,000 Page 2 Vol. I Page 435 Aggregate Production Quotas (all values are in grams unless indicated otherwise) Controlled Substance Final Revised Initial Final Revised Proposed Initial Initial Oripayijie _ 15,000,000 15,000,000 5,000,000 6,000,000 9,600, 000 Oxycodone (for conversion) . 5.600,000 " " "5.600,000 ^57600,000 5,606,000 "5,600.000 Oxy'codone'(forsate) 105,500,000 105,500,000 96.000,000 96,000,000" 9,800,000 Schedule II: . "" 2010 ' 201 f 2011 2012 2012 Oxymorphoneffor conversion) 12,800,000 _ 12,800,000 12,800,000 12.80070D01 12,800,000 Oxymorphone (for sale) ... "" 3.070,000 ' 3,070,000' 3.070,000 "" 5,500,000? " 3,070,000 Pentobarbital . 28.660,006 _ 28,660,000 34,000^000 31 ,000,0001 34,000.000 Phenazccine 1 5 _5i 5 5 Phencydidine . 24 24 24 24 Phenme!»02ina 2 2 2 2 2 Phenyiacetone7_ „ 12,500,001 8,000.000 e.ooo,oool 8,000,000 16,000*,"000 Pr?perid^ie 2 Racemethorphan 2 2 2 " 2 2 Remifentanil 2,500 2,500 2,500 2,500" 2,500 Secobarbital "67,000 260,002 336,002 336,002 336,002 Sufentanil 7,OOql _ _71000| 5,000 _ 5,000 5,000 Tapentadol ' 1600",oo'o" *" 1.000,006 403.000 l'_ 243,000 " 5.406606 thebaine 126,000,OOOl "126.000,000 116,666,000 116",O'OO.OOO 11,600,000 PageS Vol. I Page 436 Dr"g Proposed APQ Establish APQ Change 3,4-Methylenedioxy-N-melhylcathinone (melhylone) 8.0 8.0 3,4-Methylenedioxypyrovalerone (MDPV) 8.0 8.0 4-Meihyl-N-methylcathinone (mephedrone) 8.0 8.0 11,600.0 IS.000.0 3,400.0 alfentanil i dihydrocodeine 255,000.0 400,000.0 145,000.0 500.000.0 900,000.0 400,000.0 diphenoxylate i gamma hydroxybutyric acid 29,000,000.0 47,000,000.0 18,000,000.0 hydromorphinol 2.0 54.0 52.0 lisdexamfetamine 10.400,000.0 12,000,000.0 1,600,000.0 meperidine 5,200,000.0 5,500,000.0 300,000.0 meperidine - intermediate A 3.0 5.0 2.0 meperidine - intermediate B 7.0 9.0 2.0 meperidine - intermediate C 3.0 5A 2.0 morphine-N-oxidc 6054)' 655.0 50.0 10,502.0 20.502.0 10.000.0 nabilone i i pentobarbital 31,000,000.0 34,000,000.0 3,000,000.0 phenylacetone 8.000,000.0 16,000,000.0 8,000,000.0 properidine 2.0 2.0 tapentadol 243,000.0 5,400,000.0 5,157,000.0 Vol.
Load more

Recommended publications
  • Minnesota Statutes 1979 Supplement
    MINNESOTA STATUTES 1979 SUPPLEMENT 152.01 PROHIBITED DRUGS CHAPTER 152. PROHIBITED DRUGS Sec. 152.01 Definitions. 152.02 Schedules of controlled substances; admin­ istration of chapter. 152.01 Definitions. [For text of subds 1 to 8, see M.S.1978] Subd. 9. Marijuana. "Marijuana" means all parts of the plant of any species of the genus Cannabis, including all agronomical varieties, whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin, but shall not include the mature stalks of such plant, fiber from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mix­ ture, or preparation of such mature stalks, except the resin extracted therefrom, fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination. [For text of subds 10 to 17, see M.S.1978] [ 1979 c 157 s 1 ] 152.02 Schedules of controlled substances; administration of chapter. [For text of subd 1, see M.S.1978) Subd. 2. The following items are listed in Schedule I: (1) Any of the following substances, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the exis­ tence of such isomers, esters, ethers and salts is possible within the specific chemical des­ ignation: Acetylmethadol; Allylprodine; Alphacetylmethadol; Alphameprodine; Alpham- ethadol; Benzethidine; Betacetylmethadol; Betameprodine; Betamethadol; Betaprodine; Clonitazene; Dextromoramide; Dextrorphan; Diampromide; Diethyliambutene; Dime- noxadol; Dimepheptanol; Dimethyliambutene; Dioxaphetyl butyrate; Dipipanone; Ethylmethylthiambutene; Etonitazene; Etoxeridine; Furethidine; Hydroxypethidine; Ke- tobemidone; Levomoramide; Levophenacylmorphan; Morpheridine; Noracymethadol; Norlevorphanol; Normethadone; Norpipanone; Phenadoxone; Phenampromide; Pheno- morphan; Phenoperidine; Piritramide; Proheptazine; Properidine; Racemoramide; Tri­ meperidine.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • 2020 Kansas Statutes
    2020 Kansas Statutes 65-4105. Substances included in schedule I. (a) The controlled substances listed in this section are included in schedule I and the number set forth opposite each drug or substance is the DEA controlled substances code that has been assigned to it. (b) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation: (1) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N- phenylacetamide) 9821 (2) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N- phenylacetamide) 9815 (3) Acetylmethadol 9601 (4) Acryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide; acryloylfentanyl) 9811 (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) 9551 (6) Allylprodine 9602 (7) Alphacetylmethadol 9603(except levo-alphacetylmethadol also known as levo- alpha-acetylmethadol, levomethadyl acetate or LAAM) (8) Alphameprodine 9604 (9) Alphamethadol 9605 (10) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl] propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine) 9814 (11) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N- phenylpropanamide) 9832 (12) Benzethidine 9606 (13) Betacetylmethadol 9607 (14) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N- phenylpropanamide) 9830 (15) Beta-hydroxy-3-methylfentanyl (other
    [Show full text]
  • ESTIMATED WORLD REQUIREMENTS of NARCOTIC DRUGS in GRAMS for 2019 (As of 10 January 2019 )
    ESTIMATED WORLD REQUIREMENTS OF NARCOTIC DRUGS IN GRAMS FOR 2019 (as of 10 January 2019 ) Afghanistan Cannabis 50 Codeine 50 000 Cannabis resin 1 Dextropropoxyphene 10 000 Coca leaf 1 Diphenoxylate 5 000 Cocaine 15 Fentanyl 1 Codeine 650 000 Methadone 20 000 Codeine -N-oxide 1 Morphine 8 000 Dextromoramide 1 Pethidine 90 000 Dextropropoxyphene 200 000 Pholcodine 40 000 Difenoxin 1 Albania Dihydrocodeine 1 Cocaine 1 Diphenoxylate 1 Codeine 1 189 000 Dipipanone 1 Fentanyl 300 Ecgonine 2 Heroin 1 Ethylmorphine 1 Methadone 7 000 Etorphine 1 Morphine 7 800 Fentanyl 17 000 Oxycodone 2 000 Heroin 1 Pethidine 2 700 Hydrocodone 10 000 Pholcodine 1 500 Hydromorphone 4 000 Remifentanil 9 Ketobemidone 1 Sufentanil 2 Levorphanol 1 Algeria Methadone 100 000 Alfentanil 350 Morphine 1 550 000 Codeine 2 500 000 Morphine -N-oxide 1 Etorphine 1 Nicomorphine 1 Fentanyl 500 Norcodeine 1 Methadone 4 000 Normethadone 1 Morphine 9 000 Normorphine 1 Oxycodone 4 000 Opium 10 Pethidine 3 000 Oripavine 1 Pholcodine 1 500 000 Oxycodone 60 000 Remifentanil 1 Oxymorphone 1 Sufentanil 30 Pethidine 50 000 Andorra Phenoperidine 1 Cannabis 2 000 Pholcodine 1 Fentanyl 100 Piritramide 1 Methadone 1 000 Remifentanil 20 000 Morphine 500 Sufentanil 10 Oxycodone 2 000 Thebacon 1 Pethidine 500 Thebaine 70 000 Remifentanil 4 Tilidine 1 Angola Armenia Alfentanil 20 Codeine 3 000 Codeine 21 600 Fentanyl 40 Dextromoramide 188 Methadone 13 500 Dextropropoxyphene 200 Morphine 7 500 Dihydrocodeine 500 Thebaine 15 Diphenoxylate 300 Trimeperidine 1 500 Fentanyl 63 Aruba* Methadone 2 000
    [Show full text]
  • Information to Users
    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Opioid Powders Page: 1 of 9
    Federal Employee Program® 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 1 of 9 Last Review Date: March 13, 2020 Opioid Powders Description Buprenorphine Powder, Butorphanol Powder, Codeine Powder, Hydrocodone Powder, Hydromorphone Powder, Levorphanol Powder, Meperidine Powder, Methadone Powder, Morphine Powder, Oxycodone Powder, Oxymorphone Powder Background Pharmacy compounding is an ancient practice in which pharmacists combine, mix or alter ingredients to create unique medications that meet specific needs of individual patients. Some examples of the need for compounding products would be: the dosage formulation must be changed to allow a person with dysphagia (trouble swallowing) to have a liquid formulation of a commercially available tablet only product, or to obtain the exact strength needed of the active ingredient, to avoid ingredients that a particular patient has an allergy to, or simply to add flavoring to medication to make it more palatable. Buprenorphine, butorphanol, codeine, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, and oxymorphone powders are opioid drugs that are used for pain control. The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death (1-15). Regulatory Status 5.70.64 Section: Prescription Drugs Effective Date: April 1, 2020 Subsection: Analgesics and Anesthetics Original Policy Date: October 20, 2017 Subject: Opioid Powders Page: 2 of 9 FDA-approved indications: 1.
    [Show full text]
  • A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L
    Hofstra Law Review Volume 18 | Issue 3 Article 10 1990 A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation Joseph L. Galiber Follow this and additional works at: http://scholarlycommons.law.hofstra.edu/hlr Part of the Law Commons Recommended Citation Galiber, Joseph L. (1990) "A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with Regulation," Hofstra Law Review: Vol. 18: Iss. 3, Article 10. Available at: http://scholarlycommons.law.hofstra.edu/hlr/vol18/iss3/10 This document is brought to you for free and open access by Scholarly Commons at Hofstra Law. It has been accepted for inclusion in Hofstra Law Review by an authorized administrator of Scholarly Commons at Hofstra Law. For more information, please contact [email protected]. Galiber: A Bill to Repeal Criminal Drug Laws: Replacing Prohibition with R A BILL TO REPEAL CRIMINAL DRUG LAWS: REPLACING PROHIBITION WITH REGULATION Joseph L. Galiber* Conventional wisdom obliges elected officials to beat the narcodrums loudly and incessantly, and to demand increasingly harsh criminal penalties for the sale and use of illegal drugs.' It is reasonable to wonder why I, a senator, would dare submit a bill2 to the New York State Legislature which would regulate all drugs cur- rently proscribed as illegal in precisely the same manner as alcohol.3 The short answer is that the use of the criminal law to control drug use has not, and never will, have anything more than a costly and marginal impact on drug consumption.4 Despite all the public hyperventilation, drug consumption remains a private, consensual * New York State Senator; B.A.
    [Show full text]
  • CONTROLLED SUBSTANCE, DRUG, DEVICE and COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun
    CONTROLLED SUBSTANCE, DRUG, DEVICE AND COSMETIC ACT - SCHEDULE I CONTROLLED SUBSTANCES Act of Jun. 23, 2011, P.L. 36, No. 7 Cl. 35 Session of 2011 No. 2011-7 SB 1006 AN ACT Amending the act of April 14, 1972 (P.L.233, No.64), entitled "An act relating to the manufacture, sale and possession of controlled substances, other drugs, devices and cosmetics; conferring powers on the courts and the secretary and Department of Health, and a newly created Pennsylvania Drug, Device and Cosmetic Board; establishing schedules of controlled substances; providing penalties; requiring registration of persons engaged in the drug trade and for the revocation or suspension of certain licenses and registrations; and repealing an act," further providing for Schedule I controlled substances. The General Assembly of the Commonwealth of Pennsylvania hereby enacts as follows: Section 1. Section 4(1) of the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, amended November 24, 1999 (P.L.894, No.55), is amended to read: Section 4. Schedules of Controlled Substances.--The following schedules include the controlled substances listed or to be listed by whatever official name, common or usual name, chemical name, or trade name designated. (1) Schedule I--In determining that a substance comes within this schedule, the secretary shall find: a high potential for abuse, no currently accepted medical use in the United States, and a lack of accepted safety for use under medical supervision. The following controlled substances are included in this schedule: (i) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation: 1.
    [Show full text]
  • Hydromorphone
    Hydromorphone WHAT IS HYDROMORPHONE? sedation, and reduced anxiety. It may also cause Hydromorphone belongs to a class of drugs mental clouding, changes in mood, nervousness, called “opioids,” which includes morphine. It and restlessness. It works centrally (in the has an analgesic potency of two to eight times brain) to reduce pain and suppress cough. greater than that of morphine and has a rapid Hydromorphone use is associated with both onset of action. physiological and psychological dependence. WHAT IS ITS ORIGIN? What is its effect on the body? Hydromorphone is legally manufactured and Hydromorphone may cause: distributed in the United States. However, • Constipation, pupillary constriction, urinary retention, users can obtain hydromorphone from nausea, vomiting, respiratory depression, dizziness, forged prescriptions, “doctor-shopping,” impaired coordination, loss of appetite, rash, slow or theft from pharmacies, and from friends and rapid heartbeat, and changes in blood pressure acquaintances. What are its overdose effects? What are the street names? Acute overdose of hydromorphone can produce: Common street names include: Severe respiratory depression, drowsiness • D, Dillies, Dust, Footballs, Juice, and Smack progressing to stupor or coma, lack of skeletal muscle tone, cold and clammy skin, constricted What does it look like? pupils, and reduction in blood pressure and heart Hydromorphone comes in: rate • Tablets, capsules, oral solutions, and injectable Severe overdose may result in death due to formulations respiratory depression. How is it abused? Which drugs cause similar effects? Users may abuse hydromorphone tablets by Drugs that have similar effects include: ingesting them. Injectable solutions, as well as • Heroin, morphine, hydrocodone, fentanyl, and tablets that have been crushed and dissolved oxycodone in a solution may be injected as a substitute for heroin.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Additional Requested Drugs
    PART 1 PART PATIENT PRESCRIBED MEDICATIONS: o ACTIQ o DESIPRAMINE o HYDROCODONE o MORPHINE o ROXICODONE o ADDERALL o DIAZEPAM* o HYDROMORPHONE o MS CONTIN o SOMA o ALPRAZOLAM* o DILAUDID o IMIPRAMINE o NEURONTIN o SUBOXONE o AMBIEN o DURAGESIC o KADIAN o NORCO o TEMAZEPAM o AMITRIPTYLINE o ELAVIL o KETAMINE o NORTRIPTYLINE o TRAMADOL* o ATIVAN o EMBEDA o KLONOPIN o NUCYNTA o TYLENOL #3 o AVINZA o ENDOCET o LORAZEPAM o OPANA o ULTRAM o BUPRENEX o FENTANYL* o LORTAB o OXYCODONE o VALIUM o BUPRENORPHINE o FIORICET o LORCET o OXYCONTIN o VICODIN o BUTRANS o GABAPENTIN o LYRICA o PERCOCET o XANAX o CLONAZEPAM* o GRALISE o METHADONE o RESTORIL TO RE-ORDER CALL RITE-PRINT 718/384-4288 RITE-PRINT CALL TO RE-ORDER ALLIANCE DRUG PANEL (SEE BELOW) o ALCOHOL o BARBITURATES o ILLICITS o MUSCLE RELAXANTS o OPIODS (SYN) ETHANOL PHENOBARBITAL 6-MAM (HEROIN)* CARISPRODOL FENTANYL* BUTABARBITAL a-PVP MEPROBAMATE MEPERIDINE o AMPHETAMINES SECOBARBITAL BENZOYLECGONINE NALOXONE AMPHETAMINE PENTOBARBITAL LSD o OPIODS (NATURAL) METHADONE* METHAMPHETAMINE BUTALBITAL MDA CODEINE METHYLPHENEDATE MDEA MORPHINE o NON-OPIOID o BENZODIAZEPINES MDMA ANALGESICS o OPIODS (SEMI-SYN) o ANTICONVULSIVES ALPRAZOLAM* MDPV TRAMADOL BUPRENORPHINE* GABAPENTIN CLONAZEPAM* MEPHEDRONE TAPENTADOL DIHROCODEINE PREGABALIN DIAZEPAM METHCATHINONE DESOMORPHINE o NON-BENZODIAZEPINE FLUNITRAZEPAM* METHYLONE HYDROCODONE HYPNOTIC o ANTIDEPRESSANTS FLURAZEPAM* PCP HYDROMORPHONE ZOLPIDEM* AMITRIPTYLINE LORAZEPAM THC* OXYCODONE DOXEPIN OXAZEPAM CBD ° OXYMORPHONE o MISCELLANEOUS DRUGS IMIPRIMINE
    [Show full text]
  • Pre - PA Allowance Age 12 Years of Age Or Older – Ultracet (Tramadol and Acetaminophen) and Codeine/APAP Products
    OPIOID IR COMBO DRUGS Apadaz* (benzhydrocodone-acetaminophen), Codeine-acetaminophen, Dvorah* (dihydrocodeine-caffeine-acetaminophen*), Hydrocodone-acetaminophen, Hydrocodone- acetaminophen solution 10-325mg*, Hydrocodone-ibuprofen, Nalocet* (oxycodone- acetaminophen*), Oxycodone-acetaminophen, Oxycodone-aspirin, Oxycodone-ibuprofen, Primlev*/Prolate* (oxycodone-acetaminophen*), Tramadol-acetaminophen, Trezix (dihydrocodeine-caffeine-acetaminophen) *Prior authorization for certain non-covered formulations applies only to formulary exceptions Pre - PA Allowance Age 12 years of age or older – Ultracet (tramadol and acetaminophen) and Codeine/APAP products Quantity Patients 18 years or older will be able to fill the Pre-PA Allowance after they have filled an initial 7 day supply of IR opioid therapy or if they have been on IR or ER opioid therapy in the last 180 days Patients age 17 and under will require a PA after they have filled a 3 day supply of the Pre- PA Allowance Patients with opioid addiction treatment or methadone in the last 30 days will not be eligible for Pre-PA Allowance Immediate Release Tablets or Capsules ≤ 50 MME/day Medication Strength Quantity Limit Codeine/APAP soln 120-12 mg/5 mL Hydrocodone/APAP soln 7.5/325 mg/15 mL 5400 mL per 90 days Hydrocodone/APAP elixir 10/300 mg/15 mL Oxycodone/APAP soln 5-325 mg/5 mL 3000 mL per 90 days Hydrocodone/ibuprofen 5/200 mg, 7.5/200 mg, 10/200 mg 270 units per 90 days Oxycodone/ibuprofen 5/400 mg Oxycodone/APAP 10/325 mg Codeine/APAP 60/300 mg Hydrocodone/APAP 7.5/300 mg, 7.5/325
    [Show full text]